



Clinical trial results:

A trial to compare the injection site pain experience of 0.25 mg Semaglutide B and Semaglutide D administered sc

Summary

EudraCT number	2019-003654-83
Trial protocol	NL
Global end of trial date	04 January 2020

Results information

Result version number	v1 (current)
This version publication date	07 January 2021
First version publication date	07 January 2021

Trial information

Trial identification

Sponsor protocol code	INS-4603
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04143945
WHO universal trial number (UTN)	U1111-1239-7955

Notes:

Sponsors

Sponsor organisation name	Novo Nordisk A/S
Sponsor organisation address	Novo Allé, Bagsvaerd, Denmark, 2880
Public contact	Clinical Reporting Anchor and Disclosure (1452), Novo Nordisk A/S, +1 866 8677178, clinicaltrials@novonordisk.com
Scientific contact	Clinical Reporting Anchor and Disclosure (1452), Novo Nordisk A/S, +1 866 8677178, clinicaltrials@novonordisk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 June 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 January 2020
Global end of trial reached?	Yes
Global end of trial date	04 January 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective is to compare, in healthy subjects, the injection site pain experience of a single dose of 0.25 mg semaglutide subcutaneously (sc) given as the DV3396 product, to that of the PDS290 product.

Protection of trial subjects:

The trial was conducted in accordance with the Declaration of Helsinki, adopted by the 18th World Medical Association (WMA) General Assembly, Helsinki, Finland, June 1964, and subsequent amendments and International Council for Harmonisation (ICH) Good Clinical Practice (GCP) European Medicines Agency (EMA)/Committee for Medicinal Products for Human Use CHMP/ICH/135/1995), including archiving of essential documents and the European Union Clinical Trial Directive (CTD)2001/20/EC.

Background therapy:

Not applicable

Evidence for comparator:

Not applicable

Actual start date of recruitment	28 October 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 104
Worldwide total number of subjects	104
EEA total number of subjects	104

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	85
From 65 to 84 years	19
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The trial was conducted at one site in the Netherlands.

Pre-assignment

Screening details:

Subjects were randomised in a 2x2 scheme evenly to 4 sequences (A,B,C and D) of either DV3396 or PDS290 and side of injection (right/left) on abdomen.

Period 1

Period 1 title	Treatment Period 1 (Day 1)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

Investigator and subject were blinded to treatment. Qualified, unblinded members of study staff not otherwise involved in the trial procedures were responsible for trial drug administration in order to maintain blinding. To maintain blinding of subjects, a visual blind was in place during dose administration.

Arms

Are arms mutually exclusive?	Yes
Arm title	Sequence A: DV3396 (Right) then PDS290 (Left)

Arm description:

Subjects were to receive a subcutaneous (s.c.) injection of DV3396 product (0.25 milligrams (mg) of semaglutide) on the right side of abdomen (in treatment period 1); followed by an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Arm type	Experimental
Investigational medicinal product name	DV3396
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) on right side of abdomen in treatment period 1 on Day 1.

Investigational medicinal product name	PDS290
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on left side of abdomen in treatment period 2 on Day 1.

Arm title	Sequence B: DV3396 (Left) then PDS290 (Right)
------------------	-----------------------------------------------

Arm description:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 1); followed by an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	DV3396
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) on left side of abdomen in treatment period 1 on Day 1.

Investigational medicinal product name	PDS290
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on right side of abdomen in treatment period 2 on Day 1.

Arm title	Sequence C: PDS290 (Right) then DV3396 (Left)
------------------	-----------------------------------------------

Arm description:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 1); followed by an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Arm type	Experimental
Investigational medicinal product name	PDS290
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on right side of abdomen in treatment period 1 on Day 1.

Investigational medicinal product name	DV3396
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) on left side of abdomen in treatment period 2 on Day 1.

Arm title	Sequence D: PDS290 (Left) then DV3396 (Right)
------------------	-----------------------------------------------

Arm description:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 1); followed by an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Arm type	Experimental
Investigational medicinal product name	PDS290
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on left side of abdomen in treatment period 1 on Day 1.

Investigational medicinal product name	DV3396
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive a s.c. injection of DV3396 product (0.25 mg of semaglutide) on right side of abdomen in treatment period 2 on Day 1.

Number of subjects in period 1	Sequence A: DV3396 (Right) then PDS290 (Left)	Sequence B: DV3396 (Left) then PDS290 (Right)	Sequence C: PDS290 (Right) then DV3396 (Left)
Started	26	26	26
Completed	26	26	26

Number of subjects in period 1	Sequence D: PDS290 (Left) then DV3396 (Right)
Started	26
Completed	26

Period 2

Period 2 title	Treatment Period 2 (Day 1)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Sequence A: DV3396 (Right) then PDS290 (Left)

Arm description:

Subjects were to receive a subcutaneous (s.c.) injection of DV3396 product (0.25 milligrams (mg) of semaglutide) on the right side of abdomen (in treatment period 1); followed by an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Arm type	Experimental
Investigational medicinal product name	DV3396
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) on right side of abdomen in treatment period 1 on Day 1.

Investigational medicinal product name	PDS290
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on left side of abdomen in treatment period 2 on Day 1.

Arm title	Sequence B: DV3396 (Left) then PDS290 (Right)
------------------	-----------------------------------------------

Arm description:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 1); followed by an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Arm type	Experimental
Investigational medicinal product name	DV3396
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) on left side of abdomen in treatment period 1 on Day 1.

Investigational medicinal product name	PDS290
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on right side of abdomen in treatment period 2 on Day 1.

Arm title	Sequence C: PDS290 (Right) then DV3396 (Left)
------------------	-----------------------------------------------

Arm description:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 1); followed by an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Arm type	Experimental
Investigational medicinal product name	PDS290
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on right side of abdomen in treatment period 1 on Day 1.

Investigational medicinal product name	DV3396
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) on left side of abdomen in treatment period 2 on Day 1.

Arm title	Sequence D: PDS290 (Left) then DV3396 (Right)
------------------	-----------------------------------------------

Arm description:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 1); followed by an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Arm type	Experimental
Investigational medicinal product name	PDS290
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on left side of abdomen in treatment period 1 on Day 1.

Investigational medicinal product name	DV3396
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were to receive a s.c. injection of DV3396 product (0.25 mg of semaglutide) on right side of abdomen in treatment period 2 on Day 1.

Number of subjects in period 2	Sequence A: DV3396 (Right) then PDS290 (Left)	Sequence B: DV3396 (Left) then PDS290 (Right)	Sequence C: PDS290 (Right) then DV3396 (Left)
Started	26	26	26
Completed	26	26	26

Number of subjects in period 2	Sequence D: PDS290 (Left) then DV3396 (Right)
Started	26
Completed	26

Baseline characteristics

Reporting groups

Reporting group title	Treatment Period 1 (Day 1)
-----------------------	----------------------------

Reporting group description:

Subjects were to receive 1 s.c. injection of 0.25 mg semaglutide; either PDS290 product or DV3396 product from any of the sequences A/B/C/D on Day 1.

Reporting group values	Treatment Period 1 (Day 1)	Total	
Number of subjects	104	104	
Age Categorical Units: Subjects			
Age Continuous Units: years arithmetic mean standard deviation	39.1 ± 18.3	-	
Gender Categorical Units: Subjects			
Female	59	59	
Male	45	45	

End points

End points reporting groups

Reporting group title	Sequence A: DV3396 (Right) then PDS290 (Left)
-----------------------	-----------------------------------------------

Reporting group description:

Subjects were to receive a subcutaneous (s.c.) injection of DV3396 product (0.25 milligrams (mg) of semaglutide) on the right side of abdomen (in treatment period 1); followed by an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Reporting group title	Sequence B: DV3396 (Left) then PDS290 (Right)
-----------------------	-----------------------------------------------

Reporting group description:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 1); followed by an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Reporting group title	Sequence C: PDS290 (Right) then DV3396 (Left)
-----------------------	-----------------------------------------------

Reporting group description:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 1); followed by an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Reporting group title	Sequence D: PDS290 (Left) then DV3396 (Right)
-----------------------	-----------------------------------------------

Reporting group description:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 1); followed by an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Reporting group title	Sequence A: DV3396 (Right) then PDS290 (Left)
-----------------------	-----------------------------------------------

Reporting group description:

Subjects were to receive a subcutaneous (s.c.) injection of DV3396 product (0.25 milligrams (mg) of semaglutide) on the right side of abdomen (in treatment period 1); followed by an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Reporting group title	Sequence B: DV3396 (Left) then PDS290 (Right)
-----------------------	-----------------------------------------------

Reporting group description:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 1); followed by an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Reporting group title	Sequence C: PDS290 (Right) then DV3396 (Left)
-----------------------	-----------------------------------------------

Reporting group description:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 1); followed by an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Reporting group title	Sequence D: PDS290 (Left) then DV3396 (Right)
-----------------------	-----------------------------------------------

Reporting group description:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) on the left side of abdomen (in treatment period 1); followed by an s.c. injection of DV3396 product (0.25 mg of semaglutide) on the right side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.

Subject analysis set title	DV3396
----------------------------	--------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Subjects were to receive an s.c. injection of DV3396 product (0.25 mg of semaglutide) from any of the sequences A/B/C/D on Day 1.

Subject analysis set title	PDS290
----------------------------	--------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Subjects were to receive an s.c. injection of PDS290 product (0.25 mg of semaglutide) from any of the sequences A/B/C/D on Day 1.

Primary: Intensity of injection site pain

End point title	Intensity of injection site pain
-----------------	----------------------------------

End point description:

The intensity of pain was measured on a visual analogue scale (VAS). The VAS consists of a horizontal 100 millimetres (mm) line where 0 mm corresponded to no pain and 100 mm corresponded to unbearable pain. After each injection, the participants rated their pain perception at the VAS by marking a vertical line across the 100 mm line. The distance (mm) between the endpoint "no pain" and the vertical line on the VAS was recorded and analysed. Results are based on the per protocol (PP) set which included all subjects who had received both injections of semaglutide and had completed both intensity of injection site pain assessments.

End point type	Primary
----------------	---------

End point timeframe:

1 minute after each injection (Day 1)

End point values	DV3396	PDS290		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	104	104		
Units: score on a scale				
arithmetic mean (standard deviation)	8.3 (\pm 12.9)	5.7 (\pm 9.3)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

The intensity of pain was analysed by a fixed analysis of variance model with VAS score as the dependent variable, and product, injection side (right side, left side), injection number (first injection, second injection), and participant as fixed effects.

Comparison groups	DV3396 v PDS290
-------------------	-----------------

Number of subjects included in analysis	208
-----------------------------------------	-----

Analysis specification	Pre-specified
------------------------	---------------

Analysis type	other
---------------	-------

P-value	= 0.0395
---------	----------

Method	ANOVA
--------	-------

Parameter estimate	Estimated treatment difference
--------------------	--------------------------------

Point estimate	2.6
----------------	-----

Confidence interval

level	95 %
-------	------

sides	2-sided
-------	---------

lower limit	0.1
-------------	-----

upper limit	5.1
-------------	-----

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 to Day 28.

Results are based on safety analysis set which included all subjects who had received at least 1 injection of semaglutide (included any skin contact with trial product whether the injection was completed or not).

Adverse event reporting additional description:

Treatment emergent AE was defined as an event that had onset date on or after the day of first injection and no later than 28 days after the day of last injection. Trial was crossover and injections were given only 30 minutes apart, so it was not possible to say which product the AE was related to. Hence, AE data are presented for overall study.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	22

Reporting groups

Reporting group title	Overall Study
-----------------------	---------------

Reporting group description:

Subjects were to receive 2 s.c. injections of 0.25 mg semaglutide; 1 each of PDS290 product and DV3396 product from any of the sequences A/B/C/D on Day 1. The 2 products were administered at least 30 minutes apart from each other.

Serious adverse events	Overall Study		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 104 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Overall Study		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	28 / 104 (26.92%)		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	17 / 104 (16.35%)		
occurrences (all)	18		
Dyspepsia			
subjects affected / exposed	11 / 104 (10.58%)		
occurrences (all)	12		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported